Abstract
We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.
MeSH terms
-
Aged
-
Antifungal Agents / therapeutic use
-
Cryptococcosis / chemically induced*
-
Cryptococcosis / diagnosis
-
Cryptococcosis / drug therapy
-
Cryptococcus neoformans*
-
Enzyme Inhibitors / adverse effects
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use
-
Fluconazole / therapeutic use
-
Humans
-
Immunity, Cellular / drug effects
-
Janus Kinase 1 / antagonists & inhibitors*
-
Janus Kinase 2 / antagonists & inhibitors*
-
Lung / diagnostic imaging
-
Lung / microbiology
-
Male
-
Nitriles
-
Opportunistic Infections / chemically induced*
-
Opportunistic Infections / diagnosis
-
Opportunistic Infections / immunology
-
Pneumonia, Bacterial / chemically induced*
-
Pneumonia, Bacterial / diagnosis
-
Pneumonia, Bacterial / drug therapy
-
Primary Myelofibrosis / drug therapy
-
Primary Myelofibrosis / immunology
-
Pyrazoles / adverse effects*
-
Pyrazoles / pharmacology
-
Pyrazoles / therapeutic use
-
Pyrimidines
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Antifungal Agents
-
Enzyme Inhibitors
-
Nitriles
-
Pyrazoles
-
Pyrimidines
-
ruxolitinib
-
Fluconazole
-
Janus Kinase 1
-
Janus Kinase 2